November 4th, 2026Myeloma's Gray Zones: Sequencing, Oral Therapy, and FrailtyAt the 2026 National Summit on Hematologic Cancers, Kate Kennedy, MSN, APRN, flagged decisions where guidelines give nurses and APPs little direction.Read more
November 3rd, 2026Inside an APP-Led Outpatient Clinic for Bispecific Step-Up DosingKate Kennedy, MSN, APRN, explains how Vanderbilt-Ingram's award-winning APP clinic moved bispecific step-up dosing out of the hospital.Read more
November 17th, 2026From Oncology Nurse to Care Partner: Lessons From a Couple Facing NMIBCJoAnne Page, RN, a breast cancer survivor, shares what oncology nurses can do for care partners of patients with bladder cancer.Read more
November 16th, 2026FDA Approves Giredestrant Plus Everolimus for ESR1-Mutated Breast CancerGiredestrant (Wilserdly) plus everolimus nearly doubled median PFS vs standard endocrine therapy plus everolimus in ESR1-mutated disease in evERA.Read more
November 16th, 2026FDA Approves Generic Binimetinib for BRAF-Mutant Melanoma and NSCLCAlembic's generic binimetinib, in 15 mg and 45 mg tablets, is therapeutically equivalent to Mektovi for BRAF-mutant melanoma and NSCLC.Read more
November 16th, 2026Nurse Navigation and Long-Term Cancer Survivorship InsightsThe field of oncology continues to evolve, driven by novel drug approvals, innovative delivery technologies, and emerging care strategies in cancer survivorship.Read more
November 16th, 2026FDA Approves Pertuzumab Biosimilar Pebrilzo for HER2+ Breast CancerPertuzumab-qcay is the second FDA-approved biosimilar to Perjeta, but a settlement with Genentech delays its US launch until Q3 2028.Read more
November 16th, 2026FDA Declines Ivonescimab Approval in EGFR+ NSCLC Over Survival DataThe FDA declined to approve ivonescimab plus chemotherapy after EGFR TKI therapy, citing no statistically significant OS gain in HARMONi.Read more